“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, Otsuka Still Working Out Specifics for Cooperation in Field of Oncology
August 27, 2012
- Forest HD Considering Joint Venture in Indonesia
August 24, 2012
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
- Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey
August 23, 2012
- Janssen Pharmaceutical Appoints Goodwin as Next President
August 23, 2012
- Inavir Significantly Prevents Influenza Infection in PIII: Daiichi Sankyo
August 23, 2012
- Eli Lilly Japan Not to File for Listing of Bydureon Due to Expected Rights Return
August 22, 2012
- Shionogi to Launch Quick Flu Diagnostic Kit on September 11
August 22, 2012
- Neoral, Sandimmune Approved for Small Intestine Transplantation: Novartis
August 22, 2012
- Eisai’s Halaven Receives Orphan Drug Designation for Soft-Tissue Sarcoma in US
August 22, 2012
- Pazopanib Approved for aSTS in Europe: GSK
August 22, 2012
- Oncology Japan 2012 to Be Held on November 7, 8
August 22, 2012
- Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
- ARB Prescription Rate Affected by Doctors’ Evaluations of MRs: M3 Survey
August 21, 2012
- Generic Actos Launched in US; Takeda Grants AG to Teva, Ranbaxy
August 21, 2012
- Astellas to Build New Building to Boost Production Capacity of Investigational Anticancer Drug Substances
August 21, 2012
- DSP to Set Up Cancer Institute Led by CEO of Its US Subsidiary BBI
August 21, 2012
- Synagis IM Liquid Injection Solution Approved: Abbott Japan
August 20, 2012
- Pfizer Terminates Development of AD Treatment Bapineuzumab
August 20, 2012
- RIBOMIC Acquired Patent for Analgesic Agent Containing Aptamer
August 20, 2012
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…